We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-14.6%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$771M
AUM Growth
-$198M
Cap. Flow
-$50.7M
Cap. Flow %
-6.57%
Top 10 Hldgs %
57.03%
Holding
73
New
7
Increased
16
Reduced
17
Closed
26

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$40.3M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$30.7M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$21.1M
4
ASND icon
Ascendis Pharma A/S
ASND
+$20.3M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$19.2M

Top Sells

Rank Stock Value
1
ALGS icon
Aligos Therapeutics
ALGS
+$36.9M
2
RPTX
Repare Therapeutics
RPTX
+$35.9M
3
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$22.8M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$15.5M
5
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
1
Cytokinetics
CYTK
$10.9B
$59.4M 7.71%
1,615,000
+290,000
+22% +$10.3M
ALXO icon
2
ALX Oncology
ALXO
$280M
$50.9M 6.6%
3,011,352
+105,000
+4% +$1.79M
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
$45.7M 5.93%
900,000
-100,000
-10% -$4.41M
DSGN icon
4
Design Therapeutics
DSGN
$748M
$45.2M 5.86%
2,797,501
+25,000
+0.9% +$383K
NBIX icon
5
Neurocrine Biosciences
NBIX
$17.9B
$44.5M 5.77%
+475,000
New +$40.3M
GBT
6
DELISTED
Global Blood Therapeutics, Inc.
GBT
$43.3M 5.61%
1,250,000
+500,000
+67% +$14.9M
KRTX
7
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$43.1M 5.59%
340,000
+40,000
+13% +$4.5M
BCYC
8
Bicycle Therapeutics
BCYC
$275M
$41.7M 5.4%
950,000
+80,000
+9% +$3.74M
VTYX
9
DELISTED
Ventyx Biosciences
VTYX
$34.1M 4.42%
2,514,280
+690,000
+38% +$9.22M
IDYA icon
10
IDEAYA Biosciences
IDYA
$3.5B
$31.9M 4.13%
2,850,000
+1,300,000
+84% +$19.2M
ISEE
11
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$30.3M 3.93%
1,800,000
+500,000
+38% +$7.39M
ARQT icon
12
Arcutis Biotherapeutics
ARQT
$3.55B
$28.9M 3.75%
1,500,000
+1,250,000
+500% +$21.1M
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$28.8M 3.73%
350,000
+300,000
+600% +$30.7M
KZR
14
DELISTED
Kezar Life Sciences
KZR
$26.8M 3.48%
161,402
+16,402
+11% +$2.35M
DICE
15
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$26.5M 3.44%
1,385,251
-279,000
-17% -$4.98M
DYN icon
16
Dyne Therapeutics
DYN
$4.2B
$26.4M 3.42%
2,734,392
-500,000
-15% -$4.26M
FULC icon
17
Fulcrum Therapeutics
FULC
$251M
$23.6M 3.07%
1,000,000
+315,000
+46% +$4.46M
ASND icon
18
Ascendis Pharma A/S
ASND
$16.8B
$20.5M 2.66%
+175,000
New +$20.3M
IOVA icon
19
Iovance Biotherapeutics
IOVA
$2.26B
$16.6M 2.16%
+1,000,000
New +$15.5M
OLMA icon
20
Olema Pharmaceuticals
OLMA
$1.07B
$15.9M 2.07%
3,743,875
– –
LONA
21
LeonaBio Inc
LONA
$69.6M
$9.68M 1.26%
71,729
-91,345
-56% -$9.63M
JNCE
22
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$9.51M 1.23%
1,400,000
+50,000
+4% +$356K
VERA icon
23
Vera Therapeutics
VERA
$2.57B
$9.04M 1.17%
385,000
+335,000
+670% +$7.21M
SRRK icon
24
Scholar Rock
SRRK
$5.91B
$8.7M 1.13%
+675,000
New +$11.5M
ANAB icon
25
AnaptysBio
ANAB
$1.61B
$7.42M 0.96%
+300,000
New +$9.08M
1
2 3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q1 2022 Portfolio in Review

As of Q1 2022, Logos Global Management held 73 positions worth $771M, down 20% from $970M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Logos Global Management withdrew a net $50.7M in Q1 2022, closing 26 positions and reducing 17 holdings. Its most notable exit was Aligos Therapeutics, an estimated $36.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Neurocrine Biosciences worth $44.5M.

  • Logos Global Management's largest Q1 2022 buy was Neurocrine Biosciences: 475,000 shares worth $44.5M.
  • Logos Global Management added most to Mirati Therapeutics, Inc. Common Stock in Q1 2022, an estimated $30.7M increase.
  • Logos Global Management's biggest Q1 2022 reduction was Verve Therapeutics, cutting an estimated $9.9M.
  • Logos Global Management fully exited Aligos Therapeutics in Q1 2022, selling an estimated $36.9M.
  • Logos Global Management's ten largest holdings make up 57% of its $771M portfolio in Q1 2022.
  • Logos Global Management opened 7 new positions and closed 26 in Q1 2022.
  • Logos Global Management's portfolio value fell 20% quarter-over-quarter to $771M.

Based on Logos Global Management's 13F filing for Q1 2022, filed 16 May 2022.